Project description
A multilevel campaign to boost colorectal cancer screening
Population-based screening for colorectal cancer (CRC) is recommended in the EU. Accounting for 12.4 % of all cancer deaths, only one in seven EU citizens participate in screening programmes. The EU-funded ONCOSCREEN project aims to reverse this trend by promoting accurate, non-invasive, cost-effective screening tests based on new technologies and an increased awareness on the disease. Personalised approaches for screening are needed to consider genetic and other socioeconomic variables and environmental stressors. With this in mind, the project will develop a risk-based, population-level stratification methodology for CRC to account for genetic prevalence, socioeconomic status and other factors. Bringing together a 38-partner consortium, the project is in line with Horizon Europe’s Cancer Mission.
Objective
With Colorectal Cancer (CRC) being accountable for 12.4% of all deaths due to cancer, and with only 14% of EU citizens participating in screening programmes, there is an urgent need for accurate, non-invasive, cost-effective screening tests based on novel technologies and an increased awareness on the disease and its detection. Furthermore, personalized approaches for screening are needed, to consider genetic and other socioeconomic variables and environmental stressors that lead to different onsets of the disease. ONCOSCREEN responds to these challenges by developing a risk-based, population-level stratification methodology for CRC, to account for genetic prevalence, socio-economic status, and other factors. It complements this methodology by a) developing a set of novel, practical, and low-cost screening technologies with high sensitivity and specificity, b) leveraging AI to improve existing methodologies for CRC screening, allowing for the early detection of polyps and provision of a personalized risk status stratification, and c) providing a mobile app for self-monitoring and CRC awareness raising. Furthermore, ONCOSCREEN develops an Intelligent Analytics dashboard for policy makers facilitating effective policy making at regional and national levels. Through a multi-level campaign, the above-mentioned solutions are tested and validated. For the clinical solutions specifically, a clinical validation study has been planned with the participation of 4100 enrolled patients/citizens. To ensure the adoption of the developed solutions by the healthcare systems, their cost-effectiveness and financial viability will be assessed. The 48-months duration project will be implemented by a multidisciplinary consortium comprising of 38 partners, including technical solutions providers, hospitals, Ministries of Health as policy makers, legal and ethics experts, Insurance companies, involving actively end-users/citizens in all phases of implementation through targeted workshops. This action is part of the Cancer Mission cluster of projects on ‘Prevention, including Screening.
Fields of science
Programme(s)
- HORIZON.2.1 - Health Main Programme
Funding Scheme
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinator
118 54 ATHENS
Greece
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participants (39)
55131 Mainz
See on map
106 82 ATHINA
See on map
68330 Huningue
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
23562 Lübeck
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
23562 Lubeck
See on map
44307 Kaunas
See on map
8010 Graz
See on map
4200-072 Porto
See on map
022328 Bucharest
See on map
32000 Haifa
See on map
4704 553 Braga
See on map
5037 AB Tilburg
See on map
2400 Mol
See on map
57001 Thermi Thessaloniki
See on map
1200 Bruxelles / Brussel
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
14467 POTSDAM
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
3001 Leuven
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1040 Nicosia
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Dundalk Co Louth
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
010158 Bucuresti
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
26006 La Rioja
See on map
1000 Bruxelles / Brussel
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
A96 PR60 Dublin
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
. ATHINA
See on map
44307 Kaunas
See on map
4200-172 Porto
See on map
124 61 CHAIDARI ATHINA
See on map
1090 Wien
See on map
400372 Cluj Napoca
See on map
6020 Innsbruck
See on map
LT 01506 Vilnius
See on map
20123 Milano
See on map
28006 Madrid
See on map
25000 Besancon
See on map
1000 Sofia
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
75008 Paris
See on map
75011 Paris
See on map
See on map
See on map